Corrigendum to "Randomized phase 2 trial and open-label extension of domagrozumab in Duchenne muscular dystrophy" [Neuromuscular Disorders, Vol. 30 (6) 2020, 492-502]

Affiliations

• ¹ Center for Genetic Muscle Disorders, Baltimore, Kennedy Krieger Institute, Departments of Neurology and Neuroscience, Johns Hopkins School of Medicine, Baltimore, MD, USA. Electronic address: wagnerk@kennedykrieger.org.
• ² University of Pittsburgh, Pittsburgh, PA, USA.
• ³ Cumming School of Medicine, University of Calgary, Alberta Children's Hospital, Calgary, AB, Canada.
• ⁴ Department of Pediatrics, Clinical Neurological Sciences and Epidemiology, University of Western Ontario, Children's Hospital London Health Sciences Centre, London, ON, Canada.
• ⁵ The John Walton Muscular Dystrophy Research Centre, Newcastle University and Newcastle Hospitals NHS Foundation Trust, Newcastle upon Tyne, UK.
• ⁶ NIHR Great Ormond Street Hospital Biomedical Research Centre, Great Ormond Street Institute of Child Health, University College London, & Great Ormond Street Hospital Trust, London, UK.
• ⁷ Hyogo College of Medicine, Nishinomiya, Hyogo, Japan.
• ⁸ Lawson Health Research Institute: Children's Hospital, London, ON, Canada.
• ⁹ Department of Neurology, Medical University of Warsaw, Warsaw, Poland.
• ¹⁰ University of Minnesota, Minneapolis, MN, USA.
• ¹¹ University of Utah School of Medicine, Salt Lake City, UT, USA.
• ¹² Paediatric Neurology, Catholic University, Rome, Italy; Centro Clinico Nemo, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Rome, Italy.
• ¹³ IRCCS Giannina Gaslini, Genova, Italy.
• ¹⁴ Bambino Gesu Children's Research Hospital IRCCS, Rome, Italy.
• ¹⁵ Cincinnati Children's Hospital Medical Center; College of Medicine University of Cincinnati, Cincinnati, OH, USA.
• ¹⁶ University of Kansas Medical Center, Kansas City, KS, USA.
• ¹⁷ Pfizer Inc, New York, NY, USA.
• ¹⁸ Pfizer Inc, Cambridge, MA, USA.
• ¹⁹ University of Massachusetts Medical School, Worcester, MA, USA.